- Home
- MCVT vs CANF Comparison
MCVT vs CANF Comparison
Compare MCVT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCVT
- CANF
- Stock Information
- Founded
- MCVT 2007
- CANF 1994
- Country
- MCVT United States
- CANF Israel
- Employees
- MCVT N/A
- CANF N/A
- Industry
- MCVT Finance Companies
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- MCVT Finance
- CANF Health Care
- Exchange
- MCVT Nasdaq
- CANF Nasdaq
- Market Cap
- MCVT 11.6M
- CANF 14.4M
- IPO Year
- MCVT N/A
- CANF N/A
- Fundamental
- Price
- MCVT $1.96
- CANF $1.54
- Analyst Decision
- MCVT
- CANF Strong Buy
- Analyst Count
- MCVT 0
- CANF 2
- Target Price
- MCVT N/A
- CANF $14.00
- AVG Volume (30 Days)
- MCVT 4.5K
- CANF 1.2M
- Earning Date
- MCVT 11-12-2024
- CANF 02-03-2025
- Dividend Yield
- MCVT N/A
- CANF N/A
- EPS Growth
- MCVT N/A
- CANF N/A
- EPS
- MCVT 0.05
- CANF N/A
- Revenue
- MCVT $3,234,265.00
- CANF $667,000.00
- Revenue This Year
- MCVT N/A
- CANF $409.56
- Revenue Next Year
- MCVT N/A
- CANF N/A
- P/E Ratio
- MCVT $39.90
- CANF N/A
- Revenue Growth
- MCVT N/A
- CANF N/A
- 52 Week Low
- MCVT $1.75
- CANF $1.29
- 52 Week High
- MCVT $3.88
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- MCVT 49.28
- CANF 41.02
- Support Level
- MCVT $1.90
- CANF $1.41
- Resistance Level
- MCVT $2.06
- CANF $1.54
- Average True Range (ATR)
- MCVT 0.06
- CANF 0.10
- MACD
- MCVT 0.01
- CANF 0.02
- Stochastic Oscillator
- MCVT 44.44
- CANF 52.38
About MCVT Mill City Ventures III Ltd.
Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions primarily to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that they provide are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).